Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease:Potential therapeutic implications  

作　　者：Stergios A Polyzos Jannis Kountouras Athanasios D Anastasilakis Evangelos Terpos 

机构地区：[1]First Laboratory of Pharmacology,Medical School,Aristotle University of Thessaloniki,Thessaloniki,Macedonia,Greece [2]Second Medical Clinic,Aristotle University of Thessaloniki,Ippokration Hospital,Thessaloniki,Macedonia,Greece [3]Department of Endocrinology,424 General Military Hospital,Thessaloniki,Macedonia,Greece [4]Department of Clinical Therapeutics,School of Medicine,National and Kapodestrian University of Athens,Athens,Greece

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第4期437-438,共2页国际肝胆胰疾病杂志（英文版）

摘　　要：To the Editor:We read with considerable interest the paper of Shree Harini and Ezhilarasan,summarizing the possible pathophysiological connections between the modulators of canonical Wnt/β-catenin pathway and nonalcoholic fatty liver disease(NAFLD)[1].The au-thors supported with evidence that Wnt/β-catenin signaling contributes to hepatic homeostasis by regulating hepatic development,regeneration and metabolism.They also supported that dysregula-tion of modulators of Wnt/β-catenin signaling is not only impli-cated in the development of NAFLD,but also in its progression to nonalcoholic steatohepatitis(NASH),hepatic fibrosis and hepato-cellular carcinoma(HCC).

关 键 词：HEPATIC NAFLD NONALCOHOLIC 

分 类 号：R575.5[医药卫生—消化系统]